The industry says it keeps down the cost of prescription drugs, but critics say it's profiting at the expense of patients.

Weight-loss drug developer Metsera has raised $275 million after pricing its U.S. initial public offering at $18 per share, above its targeted range, the ARCH Venture Partners-backed biotech company ...